ZTS · Zoetis Inc.
$74.19
+0.51% last session
End-of-day data · updated 2026-07-24
Market cap
$31B
Enterprise value
$39B
Trailing P/E
12.2
Forward P/E
10.1
Dividend yield
3.0%
Beta
0.75
Avg volume
7M
Employees
14K
2D change
0.51%
5D change
-1.92%
10D change
1.38%
30D change
-3.94%
60D change
-7.66%
MTD change
3.64%
YTD change
-39.80%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ZTS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-27
Latest call per bank · past 12 months
UBS
Neutral$85.00
+14.6% vs priceMorgan Stanley
Overweight$99.00
+33.4% vs priceHSBC
Buy$95.00
+28.0% vs priceBarclays
Equal-Weight$85.00
+14.6% vs priceCitigroup
Buy$112
+51.0% vs priceJP Morgan
Overweight$130
+75.2% vs priceBank of America
Neutral$140
+88.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-27 | UBS | Maintains | Neutral | $99.00 → $85.00 |
| 2026-07-22 | Morgan Stanley | Maintains | Overweight | $115 → $99.00 |
| 2026-07-06 | HSBC | Maintains | Buy | $140 → $95.00 |
| 2026-07-01 | Barclays | Maintains | Equal-Weight | $136 → $85.00 |
| 2026-06-30 | TD Cowen | Maintains | Buy | $150 → $104 |
| 2026-06-26 | Stifel | Maintains | Hold | $95.00 → $85.00 |
| 2026-05-27 | Argus Research | Downgrade | Buy → Hold | $0.00 |
| 2026-05-22 | Stifel | Maintains | Hold | $105 → $95.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 43 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 2.7% below the 50-day MA ($76.62).
- Price vs 200-day MA: Trading 32.9% below the 200-day MA ($111.08).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+0.43) — short-term momentum is improving.
- 52-week range: Price is within 10% of the 52-week low ($71.36).
ZTS Price Chart
Loading chart for ZTS…
Fundamentals
About Zoetis Inc.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$54B 7.9% YTD
HLN
Haleon plc
$43B -2.7% YTD
TEVA
Teva Pharmaceutical Industries
$36B -0.1% YTD
UTHR
United Therapeutics Corporation
$26B 8.7% YTD
VTRS
Viatris Inc.
$20B 41.0% YTD
NBIX
Neurocrine Biosciences, Inc.
$18B 22.8% YTD
ELAN
Elanco Animal Health Incorporat
$12B 9.5% YTD
RDY
Dr. Reddy's Laboratories Ltd
$10B -16.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.